Floatz logo

Avzo-021

CCNE1 Amplification

Avenzo Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the CCNE1 Amplification cohort.

Asset / SponsorPhaseRating
Letrozole
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Carboplatin
Avenzo Therapeutics, Inc.
Phase 1/2CCC
FULVESTRANT
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Zoladex
Avenzo Therapeutics, Inc.
Phase 1/2CCC
Ribociclib
Avenzo Therapeutics, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Avzo-021 is also rated in:

breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
hormone receptor-positive breast cancerDormant
CC
Indicative ·
45 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →